# Cardiva Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardiva-medical

- Industry: Medical Devices & Equipment
- Headquarters: Santa Clara, US
- Website: www.cardivamedical.com
- Total disclosed funding: $78M
- Latest round: Series C (Aug 20, 2014)
- Investors on record: 10

## About

Cardiva Medical, Inc. is a US-based company specializing in the design and development of innovative medical technologies aimed at improving patient outcomes in the field of blood management.Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical, Inc. focuses on creating advanced solutions for managing blood in hospital and clinical settings. In January 2021, Cardiva Medical was acquired by Haemonetics Corporation for USD 475 mn, marking a strategic shift in ownership and resources to enhance their product offerings. The company was formed by a team of experts in the medical field, though specific founder information is not publicly available.Cardiva Medical, Inc. provides a range of blood management technologies that enhance surgical and clinical practices. Their core products include advanced hemostatic devices used to manage bleeding during and after invasive procedures, ensuring effective blood clotting and patient safety. The company delivers its technologies to various healthcare facilities, including hospitals and surgical centers, primarily in North America and expanding into international markets.Cardiva Medical, Inc. generates revenue through the sale of their innovative hemostatic devices and associated service agreements, focusing on business-to-business transactions with healthcare providers. Their revenue strategy includes both direct product sales and recurring income from service contracts, ensuring support and maintenance for their advanced technologies.Following the acquisition by Haemonetics Corporation in January 2021, Cardiva Medical plans to leverage additional resources for product development and market expansion. The company is exploring opportunities to introduce new hemostatic devices and enhance existing offerings, aiming to release new products by late 2022. Expansion plans include targeting additional markets in Europe and Asia-Pacific by 2023 to reach a broader clientele, with recent funding supporting these strategic initiatives.

## Funding rounds

- Series C, Aug 20, 2014 — PTV Healthcare Capital, Amkey Ventures, Triventures, Evidity Health Capital
- Series E, Mar 31, 2014, $13M — PTV Healthcare Capital
- Series B, Aug 9, 2012 — Galen Partners, PTV Healthcare Capital, Sycamore Ventures, Amkey Ventures, Triventures
- Series E, Apr 5, 2010, $10M — PTV Healthcare Capital
- Series D, May 5, 2008, $16M — Galen Partners, PTV Healthcare Capital, TaiAn Technologies Corporation, Sycamore Ventures, Amkey Ventures
- Series C, May 17, 2006, $14M — Galen Partners, WI Harper Group, Harbinger Venture Capital, Sycamore Ventures, Amkey Ventures, Stockton Partners
- Series B, May 18, 2005, $8.3M — WI Harper Group, Harbinger Venture Capital, Sycamore Ventures, Stockton Partners
- Series A, Oct 1, 2003, $11M — WI Harper Group, Harbinger Venture Capital, Sycamore Ventures
- Series A, May 1, 2003, $7M — WI Harper Group, Harbinger Venture Capital, Sycamore Ventures

## Investors

- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series A, Series B, Series C
- Harbinger Venture Capital (https://capitalatlas.ai/funds/harbinger-venture-capital) — Series A, Series B, Series C
- Sycamore Ventures (https://capitalatlas.ai/funds/sycamore-ventures) — Series A, Series B, Series C, Series D
- Stockton Partners (https://capitalatlas.ai/funds/stockton-partners) — Series B, Series C
- Galen Partners (https://capitalatlas.ai/funds/galen-partners) — Series C, Series D, Series B
- Amkey Ventures (https://capitalatlas.ai/funds/amkey-ventures) — Series C, Series D, Series B
- PTV Healthcare Capital (https://capitalatlas.ai/funds/ptv-healthcare-capital) — Series D, Series E, Series B, Series C
- TaiAn Technologies Corporation (https://capitalatlas.ai/funds/taian-technologies-corporation) — Series D
- Triventures (https://capitalatlas.ai/funds/triventures) — Series B, Series C
- Evidity Health Capital (https://capitalatlas.ai/funds/evidity-health-capital) — Series C